Proceedings of ICMMGH 2027 Symposium: Clinical OMICS for Drug Discovery and Personalized Medicine
DOI: 10.54254/2753-8818/2027.MB38068

Antitumor Pharmacological Mechanisms and Preclinical Advances of Coumarin Derivatives

Hangyu Liu

Department of Chemistry, University of Warwick, Coventry, UK
u5760358@live.warwick.ac.uk

Abstract. Coumarin is a class of benzopyrone heterocyclic compounds widely distributed in natural plants. Its relatively simple scaffold, generally low toxicity, ease of structural modification and favorable biocompatibility make it an attractive core for natural-product chemistry and anticancer drug development. However, the intrinsic antitumor activity of many natural coumarins is limited. Derivatives generated through scaffold modification, side-chain substitution and heterocyclic hybridization can substantially strengthen target-oriented anticancer activity while improving aqueous solubility and metabolic stability. Recent pharmacological evidence indicates that coumarin derivatives can exert broad antitumor effects through multiple targets and pathways, including tumor-cell-cycle arrest, induction of apoptosis and autophagy, inhibition of tumor angiogenesis, blockade of proliferative signaling, reversal of multidrug resistance and regulation of the tumor microenvironment. Activity has been reported against lung, liver, breast, ovarian and gastrointestinal malignancies. This paper examines the structural characteristics and structure–activity relationships of coumarin compounds, evaluates their major antitumor pharmacological mechanisms, and synthesizes representative preclinical evidence from cellular and animal studies. It also considers efficacy-enhancing strategies involving structural optimization and combination therapy. Particular attention is given to persistent limitations, including insufficient potency in some derivatives, restricted target specificity, suboptimal drug-like properties and incomplete safety assessment. Future development should integrate rational structural optimization with target-directed delivery, pharmacokinetic validation and stronger translational models to improve the probability that coumarin-based candidates progress from promising preclinical compounds to clinically relevant anticancer agents.

Keywords: coumarin derivatives, antitumor activity, pharmacological mechanisms, preclinical research, structure–activity relationship

1. Introduction

1.1. Natural occurrence of coumarins and broad pharmacological relevance

Coumarins are found in a large variety of medicinal plants and are repeatedly cited as privileged scaffolds, the benzopyrone nucleus possessing various pharmacological activities such as anticancer

© 2026 The Authors. This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (https://creativecommons.org/licenses/by/4.0/).

DOI: 10.54254/2753-8818/2027.MB38068

activity [1]. However, a biologically privileged scaffold does not always mean a potent, clinically useful antitumor agent, as potencies and target specificity are highly sensitive to molecular substitution and to in vivo exposure to the drug. The significance of the natural scaffold in practice is therefore less important than the potential for rational scaffold variation.

1.2. Intrinsic limitations of natural coumarins in antitumor development

Natural coumarins are seldom able to address the central medicinal chemistry problem, alone. Modest activity with poor aqueous characteristics or fast metabolic clearance are other frequently observed properties of many compounds that reduce direct translational potential [2]. The main difficulty is that the parent scaffold needs to be altered in order to make it selectively active against tumor cells and not bring about new toxicities. However, future research should be directed toward understanding how far the native scaffold can be developed, instead of natural coumarins as developed anticancer candidates.

1.3. Rationale for synthetic derivatives and preclinical antitumor investigation

Structural change can be directly tested via synthetic coumarin derivatives which are important because they enable direct testing of how structural change affects target engagement, pharmacokinetics and biological outcome [3, 4]. Preclinical research is much more useful if it relates not only to mechanism and exposure and safety, but also to the concept of cytotoxicity. The reasons for studying coumarin derivatives, therefore, are not only for their ability to be synthesized, but that they may serve as a manageable scaffold that offers insight into how scaffold design can influence antitumor activity prior to going into clinical trials. This review considers the structure-activity relationships on scaffolds, several mechanisms of action in antitumor activity, preclinical evidence and the significant translatability hurdles of coumarin based anticancer candidates.

2. Coumarin scaffold modification, structure–activity relationships and in vivo metabolism

2.1. Benzopyrone scaffold and key bioactive substitution sites

Substitutions at C7 and C8 can expand the safety window, while substitutions at C3 and C4 can enhance direct binding to the target and cytotoxicity [1]. It has also been found that C4 derivatives lose activity when metabolized in the liver. All these factors are combined in Figure 1 [1-4]. Therefore, substitution-site selection should consider not only cellular inhibitory potency but also metabolic stability; cellular-level activity alone is insufficient to predict in vivo performance.




Figure 1. Key substitution sites shaping activity and metabolism (picture credit: original)

DOI: 10.54254/2753-8818/2027.MB38068

2.2. Chemical modification strategies for solubility and metabolic stability

Heterocycle substitution at C3 or C4 can be employed to improve polarity, affinity for the target, and cellular activity, particularly for those containing pyrazole, benzothiazole, or triazole [2]. In some cases, pathway selectivity, e.g., modulation of the phosphoinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR), has been accomplished. However, some important liabilities are not necessarily covered by such changes, such as metabolic lability and hepatotoxic risk as seen for some analogues relevant to breast cancer [4]. A more comprehensive method is multi-parameter optimization, which evaluates solubility, plasma stability, metabolite profiles, target engagement, and normal-cell toxicity, allowing for safe and efficient optimization of analogues.

2.3. Pharmacokinetic differences between natural coumarins and synthetic derivatives

The parent compound is metabolized to a large extent, particularly by cytochrome P450 2A6 (CYP2A6), and metabolites have systemic activity as well as the parent compound [1, 5]. The hepatotoxicity analysis indicates that the 3,4-epoxidation pathway and subsequent formation of reactive metabolites are safety issues, especially if they are not efficiently detoxified [6]. The metabolic pathways are compared in Figure 2 [1, 5, 6]. So, greater metabolic stability is not necessarily desirable, but must be optimized with a sufficient level of exposure and without accumulation or reactive metabolism in non-target organs.




Figure 2. Competing metabolic routes affecting efficacy and hepatotoxicity (picture credit: original)

3. Molecular antitumor mechanisms of coumarin derivatives

3.1. Oxidative stress regulation, apoptosis induction and cell-cycle arrest

Coumarin derivatives can induce apoptosis by reactive oxygen species (ROS) accumulation, disruption of mitochondria, Bcl-2-associated X protein/B-cell lymphoma 2 (Bax/Bcl-2) rebalancing, activation of caspases, and some analogues can block the progression through cell-cycle checkpoints [7]. However, oxidative stress is not necessarily damaging to tumor cells, and too much oxidative stress can cause damage to normal tissues, so it is important to have evidence that shows that the effects of redox disruption are specific to the tumor versus being toxic to normal tissues. The suggested order of operations is given in Figure 3 [7, 8].

DOI: 10.54254/2753-8818/2027.MB38068




Figure 3. Proposed apoptosis and cell-cycle sequence (picture credit: original)

3.2. Angiogenesis inhibition and blockade of proliferative signalling

Vascular endothelial growth factor (VEGF) inhibition and inhibition of phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathways are associated with antiangiogenic activity [7, 8]. A decrease in the expression of VEGF is less direct evidence than showing that a derivative decreases the formation of vessels in vivo or the perfusion of tumors in vivo.

3.3. Suppression of invasion and metastasis and reversal of multidrug resistance

Coumarins have been shown to inhibit matrix metalloproteinases and migration, and to suppress P-glycoprotein (P-gp) mediated drug efflux [7]. Results from drug-resistant acute myeloid leukemia (AML) models support the combination therapy: co-treatment with coumarin and doxorubicin has more potent pro-apoptotic effects and reduces efflux-mediated resistance more effectively than single-agent treatment [9]. The following mechanisms are summarized in Figure 4 [7, 9]. However, dose–response interaction models and toxicity comparisons should be performed at equivalent exposure to ensure a proper evaluation of synergy, which cannot be inferred from larger combined effects.




Figure 4. Coumarin actions relevant to metastasis and multidrug resistance (picture credit: original)

DOI: 10.54254/2753-8818/2027.MB38068

3.4. Selective antitumor activity through tumor-associated molecular targets

The rationale for synthetic coumarins is provided by targeting proteins involved in tumor associated processes, including carbonic anhydrases, tubulin, PI3K/mTOR-related proteins and signaling regulators [4, 7]. But the target selectivity of an enzyme does not make it tumor selective, as expression, permeability, and intracellular concentrations dictate the dominant target. Structure–activity data for breast cancer indicate that attractive binding profiles can be offset by rapid metabolism and short in vivo half-life [3]. This target/exposure problem can be summarized in Figure 5 [3, 4, 7]. Thus, claims of precision must be backed up by evidence of molecular binding, target engagement, differential activity in high versus low target models and adequate in vivo exposure.




Figure 5. Target engagement constrained by pharmacokinetic exposure (picture credit: original)

4. Preclinical antitumor evidence of coumarin derivatives

4.1. In vitro antitumor screening and mechanistic validation




Figure 6. Preclinical evidence ladder for coumarin derivatives (picture credit: original)

DOI: 10.54254/2753-8818/2027.MB38068

In vitro screening of coumarin derivatives has been performed against ovarian, cervical, breast and other cancer cell lines with hydroxyl-, prenyl- and heterocycle-substituted analogues [10]. A therapeutic window cannot be established without matched normal-cell controls, even when tumor-cell potency is high. These are the first layers of evidence as illustrated in Figure 6 [3, 5, 7, 8, 10].

4.2. In vivo efficacy, tissue distribution, and acute toxicity

The modified coumarin derivatives were more effective in the accumulation of tumors and less in the liver in gynecological cancer models, except for the high dose level [10]. However, because median effective dose (ED50), median toxic dose (TD50), and long-term organ-toxicity data are not available, a therapeutic index cannot be calculated. This is evident in Figure 7 [3, 5, 10]. Therefore, xenograft shrinkage is not enough, distribution, repeated-dose toxicology, pharmacokinetics and pharmacodynamic target inhibition should be evaluated in the same study.




Figure 7. In vitro–in vivo translational gap for potent coumarin derivatives (picture credit: original)

4.3. Synergistic antitumor effects of combination therapy

When used in combination with doxorubicin, coumarin has been shown to improve the killing of leukemic cells in drug-resistant AML by decreasing P-glycoprotein efflux and Bcl-2 signaling, and increasing caspase-3 activation [9]. Figure 8 shows a sensitization pathway [4, 9]. However, combination studies should take into account the difference between pharmacologic synergy and additive effects and should assess whether the coumarin–doxorubicin interaction is influenced by competitive inhibition of cytochrome P450.

DOI: 10.54254/2753-8818/2027.MB38068




Figure 8. Mechanistic basis of coumarin–doxorubicin sensitization (picture credit: original)

5. Current research bottlenecks and challenges

5.1. Potential metabolic toxicity and hepatotoxic risk in some coumarin derivatives

In fact, it has been reviewed that the detoxification pathway through CYP2A6-mediated 7-hydroxylation competes with a toxic pathway that results in 3,4-epoxidation and formation of downstream reactive metabolites [1, 5, 6].

The hepatotoxic activation may be diminished by the introduction of C7 alkoxy and bulky C8 substituents, but other structural changes may cause new hepatotoxic liabilities or may lead to organ-specific accumulation [1, 4, 6].

5.2. Preclinical safety assessment remains incomplete, and long-term toxicity data are scarce

The majority of coumarin derivatives are assessed by single dose or short-term studies, and chronic exposure, cumulative organ damage, and interactions are poorly characterized [5, 6]. Repeated dose hepatotoxicity, nephrotoxicity, hematological toxicity and gastrointestinal toxicity are poorly reported, and the protocols used to assess toxicity vary significantly between studies, limiting the ability to compare across studies [6].

5.3. Structure–activity research remains mainly in vitro, and in vivo structure–activity patterns are still unclear

One primary limitation is that most structure–activity relationship (SAR) conclusions are based on cell growth inhibition, and not on comprehensive data from in vivo sources [2, 3, 5, 10]. This is not a trivial matter as some compounds can be very potent in vitro but poorly exposed to the tumor after

DOI: 10.54254/2753-8818/2027.MB38068

in vivo metabolism, while less potent analogues can lead to higher exposure to the tumor and to lower accumulation in the liver [3, 10].

6. Conclusion

6.1. Advantages and current problems of coumarin derivatives

Coumarin derivatives still continue to be attractive for their ability to target multiple tumor-associated targets, including pathways of apoptosis, angiogenesis, invasion, and resistance, simultaneously via one scaffold [3-5, 7]. This multi-target potential, along with synthetic flexibility, is the reason why the coumarins are still being looked upon as anticancer leads. However, the current evidence base is not consistent. There are compounds with good cellular activity with poor translational support, and safety claims rely on a small number of acute experiments. This means that the key issue is not missing mechanistic potential, but a lack of in vivo evidence that mechanisms of interest can be exposed, selective, and tolerated in vivo [2, 5, 6]. Any balanced conclusion has to acknowledge the versatility of the scaffold and the existing preclinical immaturity of the scaffold.

6.2. Outlook for low-toxicity, highly active structural design and clinical translation

Potency is not a goal in itself in future development. More important, however, is to combine medicinal chemistry with pharmacokinetics, tissue distribution, and toxicology to enhance efficacy and safety by optimizing the structure. Apparent benefits of the C3/C4 hybridization include improved target engagement, and the C7/C8 substitution may decrease metabolic activation and hepatotoxicity, but these benefits have not been consistently demonstrated thus far and require further in vivo validation [2, 3, 5, 6]. Multi-model animal testing is, therefore, a necessary requirement to test translations, while repeated dose safety testing and better guidelines for structure, exposure, and outcome are necessary to link animal testing to humans. Combination strategies and delivery systems may be further developed to enhance therapeutic value, but should be justified on a mechanistic basis and not as generic enhancement tools [4, 5, 10].

References

[1] Küpeli Akkol, E., Genç, Y., Karpuz, B., Sobarzo-Sánchez, E., & Capasso, R. (2020). Coumarins and coumarin-related compounds in pharmacotherapy of cancer. *Cancers, 12*(7), 1959. https://doi.org/10.3390/cancers12071959

[2] Koley, M., Han, J., Soloshonok, V. A., Mojumder, S., Javahershenas, R., & Makarem, A. (2024). Latest developments in coumarin-based anticancer agents: Mechanism of action and structure–activity relationship studies. *RSC Medicinal Chemistry, 15*(1), 10–54. https://doi.org/10.1039/D3MD00511A

[3] Singh, A., Singh, K., Kaur, K., Singh, A., Sharma, A., Kaur, K., Kaur, J., Kaur, G., Kaur, U., Kaur, H., Singh, P., & Bedi, P. M. S. (2024). Coumarin as an elite scaffold in anti-breast cancer drug development: Design strategies, mechanistic insights, and structure-activity relationships. *Biomedicines, 12*(6), 1192. https://doi.org/10.3390/biomedicines12061192

[4] Hacholli, V. B., R, S. M., H, P. B., M, L., S, P., Kumar, A., Szeleszczuk, Ł., & Gackowski, M. (2025). Coumarin derivatives as anticancer agents: Mechanistic landscape with an emphasis on breast cancer. *Molecules, 30*(21), 4167. https://doi.org/10.3390/molecules30214167

[5] Kubrak, T. P., Makuch-Kocka, A., & Aebisher, D. (2025). Coumarins in anticancer therapy: Mechanisms of action, potential applications and research perspectives. *Pharmaceutics, 17*(5), 595. https://doi.org/10.3390/pharmaceutics17050595

[6] Pitaro, M., Croce, N., Gallo, V., Arienzo, A., Salvatore, G., & Antonini, G. (2022). Coumarin-induced hepatotoxicity: A narrative review. *Molecules, 27*(24), 9063. https://doi.org/10.3390/molecules27249063

DOI: 10.54254/2753-8818/2027.MB38068

[7] Wu, Y., Xu, J., Liu, Y., Zeng, Y., & Wu, G. (2020). A review on anti-tumor mechanisms of coumarins. *Frontiers in Oncology, 10*, 592853. https://doi.org/10.3389/fonc.2020.592853

[8] Shahbaz, M., Perween, A., Momal, U., Imran, M., Ul Hassan, M. H., Naeem, H., Mujtaba, A., Hussain, M., Alsagaby, S. A., Al Abdulmonem, W., Abdelgawad, M. A., El-Ghorab, A. H., Selim, S., Mostafa, E. M., & Al Jbawi, E. (2024). Recent perspectives on anticancer potential of coumarin against different human malignancies: An updated review. *Food Science & Nutrition, 13*(1), e4696. https://doi.org/10.1002/fsn3.4696

[9] Al-Abbas, N. S., & Shaer, N. A. (2021). Combination of coumarin and doxorubicin induces drug-resistant acute myeloid leukemia cell death. *Heliyon, 7*(3), e06255. https://doi.org/10.1016/j.heliyon.2021.e06255

[10] Şeker Karatoprak, G., Dumlupınar, B., Celep, E., Kurt Celep, I., Küpeli Akkol, E., & Sobarzo-Sánchez, E. (2024). A comprehensive review on the potential of coumarin and related derivatives as multi-target therapeutic agents in the management of gynecological cancers. *Frontiers in Pharmacology, 15*, 1423480. https://doi.org/10.3389/fphar.2024.1423480